FOR IMMEDIATE RELEASE
ACS News Service Weekly PressPac: July 21, 2021
Toward one drug to treat all coronaviruses
Journal of Proteome Research
Safe and effective vaccines offer hope for an end to the COVID-19 pandemic. However, the possible emergence of vaccine-resistant SARS-CoV-2 variants, as well as novel coronaviruses, make finding treatments that work against all coronaviruses as important as ever. Now, researchers reporting in ACS’�Journal of Proteome Research have analyzed viral proteins across 27 coronavirus species and thousands of samples from COVID-19 patients, identifying highly conserved sequences that could make the best drug targets.
Drugs often bind inside “pocketsâ€� on proteins that hold the drug snugly, causing it to interfere with the protein’s function. Scientists can identify potential drug-binding pockets from the 3D structures of viral proteins. Over time, however, viruses can mutate their protein pockets so that drugs no longer fit. But some drug-binding pockets are so essential to the protein’s function that they can’t be mutated, and these sequences are generally conserved over time in the same and related viruses. Matthieu Schapira and colleagues wanted to find the most highly conserved drug-binding pockets in viral proteins from COVID-19 patient samples and from other coronaviruses, revealing the most promising targets for pan-coronavirus drugs. Â
The team used a computer algorithm to identify drug-binding pockets in the 3D structures of 15 SARS-CoV-2 proteins. The researchers then found corresponding proteins in 27 coronavirus species and compared their sequences in the drug-binding pockets. The two most conserved druggable sites were a pocket overlapping the RNA binding site of the helicase nsp13, and a binding pocket containing the catalytic site of the RNA-dependent RNA polymerase nsp12. Both of these proteins are involved in viral RNA replication and transcription. The drug-binding pocket on nsp13 was also the most highly conserved across thousands of SARS-CoV-2 samples taken from COVID-19 patients, with not a single mutation. The researchers say that novel antiviral drugs targeting the catalytic site of nsp12 are currently in phase II and III clinical trials for COVID-19, and that the RNA binding site of nsp13 is a previously underexplored target that should be a high priority for drug development.
The authors acknowledge funding from the , the  and the .
###
The American Chemical Öйú365betÖÐÎĹÙÍø (ACS) is a nonprofit organization founded in 1876 and chartered by the U.S. Congress. ACS is committed to improving all lives through the transforming power of chemistry. Its mission is to advance scientific knowledge, empower a global community and champion scientific integrity, and its vision is a world built on science. The Öйú365betÖÐÎĹÙÍø is a global leader in promoting excellence in science education and providing access to chemistry-related information and research through its multiple research solutions, peer-reviewed journals, scientific conferences, e-books and weekly news periodical Chemical & Engineering News. ACS journals are among the most cited, most trusted and most read within the scientific literature; however, ACS itself does not conduct chemical research. As a leader in scientific information solutions, its CAS division partners with global innovators to accelerate breakthroughs by curating, connecting and analyzing the world’s scientific knowledge. ACSâ€� main offices are in Washington, D.C., and Columbus, Ohio.
Registered journalists can subscribe to the to access embargoed and public science press releases. For media inquiries, contact newsroom@acs.org.
Note: ACS does not conduct research but publishes and publicizes peer-reviewed scientific studies.
Media Contact
ACS Newsroom
newsroom@acs.org
###
La sociedad American Chemical Öйú365betÖÐÎĹÙÍø (ACS) es una organización sin fines de lucro fundada en 1876 y aprobada por el Congreso de los Estados Unidos. La ACS se ha comprometido a mejorar la vida de todas las personas mediante la transformación del poder de la quÃmica. Su misión es promover el conocimiento cientÃfico, empoderar a la comunidad global y defender la integridad cientÃfica, y su visión es un mundo construido basándose en la ciencia. La Sociedad es lÃder mundial en la promoción de la excelencia en la educación cientÃfica y en el acceso a información e investigación relacionadas con la quÃmica a través de sus múltiples soluciones de investigación, publicaciones revisadas por expertos, conferencias cientÃficas, libros electrónicos y noticias semanales periódicas de Chemical & Engineering News. Las revistas de la ACS se encuentran entre las más citadas, las más fiables y las más leÃdas en la literatura cientÃfica; sin embargo, la propia ACS no realiza investigación quÃmica. Como lÃder en soluciones de información cientÃfica, su división CAS se asocia con innovadores internacionales para acelerar los avances mediante la preservación, la conexión y el análisis de los conocimientos cientÃficos del mundo. Las sedes principales de la ACS se encuentran en Washington, D.C., y Columbus, Ohio.
Los periodistas registrados pueden suscribirse al en EurekAlert! para acceder a comunicados de prensa públicos y retenidos. Para consultas de los medios, comunÃquese con newsroom@acs.org.
Nota: ACS no realiza investigaciones, pero publica y divulga estudios cientÃficos revisados por expertos.â€�
;void(0);){kind=link}